BioLineRx Secures GLIX1 Patent, Starts Phase 1/2a Glioblastoma Trial This Month
BioLineRx reported $20.9 million cash at Dec 31, 2025, sustaining runway into H1 2027 and received USPTO allowance for a GLIX1 patent covering ~90% of cancers with protection through 2040 (plus five-year extension). It plans to initiate a Phase 1/2a trial of GLIX1 in recurrent glioblastoma by month-end, enrolling up to 30 patients.
1. Financial Position
BioLineRx held $20.9 million in cash at December 31, 2025, extending its funding runway into the first half of 2027. This position supports ongoing clinical programs without the need for immediate capital raises.
2. Patent Allowance
BioLineRx received a Notice of Allowance from the US Patent Office for GLIX1 covering cancers with cytidine deaminase expression below threshold, representing roughly 90% of cases. The patent protection extends to 2040 with potential five-year term extension, bolstering the company’s intellectual property portfolio.
3. GLIX1 Clinical Trial
GLIX1 is set to enter a Phase 1/2a first-in-human trial for recurrent and progressive glioblastoma by month-end, enrolling up to 30 patients across Northwestern University, NYU Langone Health and Moffitt Cancer Center. The Phase 1 segment will determine safety, pharmacokinetics and maximum tolerated dose, with data expected in H1 2027, followed by a Phase 2a expansion.
4. Other Pipeline Progress
In metastatic pancreatic cancer, enrollment has accelerated in the CheMo4METPANC Phase 2b motixafortide trial, with an interim analysis due in 2026. The company also continues sickle cell disease stem cell mobilization studies and reported $6.7 million in APHEXDA sales in 2025, generating $1.2 million in royalty revenue.